Thursday, 22 October 2020


MEVION S250i Selected for New Proton Therapy Center at Chinese Hospital

20 January 2020 | News

MEVION S250i Selected for New Proton Therapy Center at Jinshazhou Hospital, Guangzhou, China

image credit- shuttershock.com

image credit- shuttershock.com

Mevion Medical Systems has signed an agreement to sell a HyperSCAN® pen-scanning scanner to Jinshazhou Hospital of Guangzhou University of Chinese Medicine MEVION S250i Proton Therapy System®. This will be the first compact proton therapy system in the Guangzhou-Hong Kong-Macao Greater Bay Area. The signing ceremony was held at Jinshazhou Hospital on December 20, 2019. Nearly 100 Chinese and international tumor radiotherapy experts and hospital managers participated.

The MEVION S250i system will be integrated into the hospital's world-class international oncology medical center in Guangzhou, and treatment is expected to begin in 2021. Guangzhou is the capital city of Guangdong Province, with a population of more than 100 million. The International Oncology Medical Centre is the result of a collaboration between Golden Sands Hospital and ICON Group , Australia's leading cancer care provider . The director of the center is Dr. Yang Wang, an internationally renowned medical physicist and vice president of Jinshazhou Hospital. The center is equipped with a cutting-edge medical technology and a cutting-edge experienced medical team. The University of Wollongong, Australia will also cooperate with the Centre to provide medical physics training and teaching.

Proton therapy is an advanced form of radiotherapy that reduces unnecessary radiation doses to healthy tissues and prevents complications and secondary cancers. Mevion's leading Hyperscan Scanning technology further enhances these benefits with faster and sharper dose delivery, which can be collimated layer by layer to provide tumors with more accurate and conformable doses.

"We are very pleased to work with Mevion to make proton therapy benefit cancer patients in South China. The MEVION S250i system is the most advanced proton therapy system available today and represents the best overall proton therapy solution," said Liu Wensheng, President of Jinshazhou Hospital. . Its addition will make Jinshazhou Hospital a world-class radiotherapy center. We look forward to proton therapy to advance our cancer treatment, research capabilities and medical education. "

ICON Group CEO Mark Middleton said: "It is exciting that the International Oncology Medical Center and ICON Group will be able to use the most advanced proton technology provided by Mevion. I believe that Golden Sands Hospital, ICON Group, Mevion and the University of Wollongong Cooperation between them will have a bright future. "

Dr. Lawrence Yuan Tian, Chairman of Mevion Medical Systems, said: "Mevion pioneered the world's first compact single-chamber proton therapy system. Since its inception, Mevion has led the revolution in compact proton therapy because this advanced cancer treatment technology has been Widely adopted worldwide. We are proud to partner with Jinshazhou Hospital and ICON Group to bring the most accurate radiation therapy to patients in the Greater Bay Area and surrounding areas. "

The sale of the MEVION S250i system to Golden Sands is yet another tangible step for Mevion's ambitious and expanding presence in China and the Asia-Pacific region. Dr. Tina Yu, CEO of Mevion Medical Systems, said: "Combining the technical advantages of our products with a strong Chinese team, Mevion is well positioned to take full advantage of China's rapidly growing proton market. High-end medical institutions in China signed a framework agreement with us last year. , We are expected to deliver our accelerator to Allcure Kangtai in 2020. Our partnership with Jinshazhou Hospital marks another important milestone in Mevion's global growth. "


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account